Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

41 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-10-31

Study Completion Date

2017-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

One of the treatments generally used to treat this disease is a chemotherapy called FOLFIRI. The purpose of this study is to improve the efficacy of the chemotherapy by adding a protein, similar to immunoglobulins, aflibercept, and to assess their tolerance.

Aflibercept is a protein that has already been studied in the treatment of metastatic colorectal cancers, in combination with a chemotherapy involving irinotecan in addition to 5FU (fluoropyrimidine) ( (FOLFIRI) as 2nd line treatment. It is marketed in Europe and it is authorized in the United States. Its addition to this chemotherapy combination has in fact brought about a benefit in terms of progression-free survival and overall survival.

The purpose of the study is to evaluate the efficacy and tolerance of this combination rather in the initial approach to the treatment of metastatic colorectal cancers and hence to evaluate it as 1st line treatment

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer

NCT02045030

Metastatic Colorectal Cancer

TERMINATED PHASE2

Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers

NCT01843725

Metastatic Colorectal Cancers Metastatic Gastric Cancers Metastatic Oesophageal Cancers +3 more

COMPLETED PHASE1

Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer

NCT01963182

First Line Metastatic Colorectal Cancer

COMPLETED PHASE2

Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung

NCT00557102

Colorectal Cancer Metastatic Cancer

COMPLETED PHASE2

Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

NCT00544011

Colorectal Cancer

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastatic Colorectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FOLFIRI + Aflibercept

FOLFIRI and aflibercept (4 mg/m²) each 14 days until progression of disease

Group Type EXPERIMENTAL

FOLFIRI Protocol

Intervention Type DRUG

injection of FOLFIRI and Aflibercept every 14 days until progression of disease

Aflibercept Injection

Intervention Type DRUG

injection of FOLFIRI and Aflibercept every 14 days until progression of disease

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FOLFIRI Protocol

injection of FOLFIRI and Aflibercept every 14 days until progression of disease

Intervention Type DRUG

Aflibercept Injection

injection of FOLFIRI and Aflibercept every 14 days until progression of disease

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years
* Overall state as per WHO (World Health Organization) ≤ 2
* Life expectancy \> 3 months
* Metastatic adenocarcinoma of the rectum or of the colon histologically proven on the primary tumor or a metastasis
* Unresectable metastasis (metastases) and/or inoperable patient
* Patient eligible for a 1st line treatment associating 5 FU-Irinotecan (FOLFIRI) and aflibercept
* At least one measurable target lesion according to RECIST criteria v1.1 not previously irradiated
* Absence of prior treatment of the metastatic disease. Prior adjuvant chemotherapy completed at least 12 months before the metastatic cancer diagnosis is authorized
* Satisfactory laboratory panel: Hb\> 9 g/dl, polynuclear neutrophils \> 1500 /mm3, platelets \> 100,000/mm3, total bilirubin \< 1.5 x UNL(upper normal limit), creatinine clearance \> 50 mL/min (cockcroft-Gault formula - appendix 4), PAL (alkaline phosphatase) \< 5 x UNL, AST (aspartate aminotransferase) and ALT (alanine aminotransferases) \< 5 x UNL, GGT (gamma-glutamyltransferase) \< 5 x UNL,
* Proteinuria on urine dipstick \< 2+. If \> 2+ test 24-hour proteinuria, which should be \< 1 g

Exclusion Criteria

* Patients whose primary tumor is in place and presenting clinical symptoms (occlusion; hemorrhage)
* Brain metastases
* Gilbert's syndrome
* Uncontrolled hypercalcemia
* Hypertension not kept under control (SBP (Systolic Blood Pressure) \>150 mmHg and DBP (Diastolic Blood Pressure) \>100 mmHg) or history of hypertensive crisis or hypertensive encephalopathy
* Any unbalanced active disease over the last 6 months: liver failure, kidney failure, respiratory failure, congestive heart failure, unstable angina, myocardial infarction, significant arrhythmia (Patients treated by anticoagulants (coumadin, warfarin) are eligible if strict monitoring of the INR( international normalized ratio) is possible)
* Significant surgical intervention within the 28 days before the start of treatment
* Presence of active gastroduodenal ulcer, non-healed wound or bone fracture
* Antitumor treatments other than those included in the study (chemotherapy, targeted therapy, immunotherapy)
* History of malignant hemopathy or cancer except for those treated more than 5 years ago and considered healed, in situ carcinomas of the uterine cervix and treated skin cancers (except for melanoma)
* Pregnant or breast-feeding women, women of childbearing age not having taken a pregnancy test, absence of effective contraception in patients (men and/or women) of childbearing age
* Any contraindication of the drugs used in the study
* Impossible to meet the medical follow-up requirements of the study for geographic, social or psychological reasons

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No